7th Gene Therapy for CNS Summit | An Intimate Networking Space for CNS GT Leaders
Unlocking Safe & Efficacious CNS Gene Therapy: Accurately Targeting CNS Disorders with Next-Gen Delivery Methods & Regulatory Alignment
The 7th Gene Therapy for CNS Summit returns to Boston this October as the only industry-led meeting dedicated to advancing gene therapies for CNS disorders. With the FDA’s first approval of a brain-delivered AAV therapy and growing momentum behind novel capsids and delivery technologies, this is your chance to stay ahead of the curve in a rapidly evolving field.
Explore the website for more information: https://ter.li/jk0fb8
This summit brings together biopharma, academia, and regulators to accelerate safe, efficacious, and scalable CNS gene therapies—spanning rare neurological conditions to prevalent neurodegenerative diseases.
Key Agenda Themes:
- Innovating Capsids & Vectors – Improve BBB penetration and reduce toxicities with cutting-edge AAV designs
- Enhancing Preclinical Translation – Leverage advanced CNS models to accelerate from discovery to clinic
- Optimizing Delivery Devices – Compare systemic vs. direct brain/CSF delivery to maximize targeting
- Streamlining Manufacturing – Mitigate early-stage bottlenecks and scale vector production efficiently
- Meeting Regulatory Expectations – Navigate IND submissions and evolving global guidance
New for 2025:
- 70% new speaker faculty including leaders from Novartis, Ultragenyx, Sanofi, Dyno Therapeutics, NysnoBio, and CLAIRIgene
- 2 interactive pre-conference workshops on Delivery Devices and Regulatory Updates
- 5+ hours of structured networking to build partnerships across CNS drug development
Hear insights from:
- Eric Kelsic, CEO & Co-Founder, Dyno Therapeutics
- James Warren, SVP Global CMC Development, Ultragenyx
- Shyam Ramachandran, Executive Director, Sanofi
- Jennifer Johnston, Co-Founder & CEO, NysnoBio
- Ralf Schmid, Associate Director, Preclinical Research, Novartis
With participation from Passage Bio, Affinia Therapeutics, Mitsubishi Tanabe Pharma, Regeneron, and more, this is your must-attend meeting to connect with peers solving the toughest challenges in CNS delivery, efficacy, and regulatory compliance.
Don’t miss your chance to be part of the only CNS-focused gene therapy meeting driving the next wave of innovation.
Secure Your Spot Here: https://ter.li/q1pyab
